IGAN
Clinical trials for IGAN explained in plain language.
Never miss a new study
Get alerted when new IGAN trials appear
Sign up with your email to follow new studies for IGAN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Kidney disease drug trial halted early – but data may still offer hope
Disease control TerminatedThis study tested a drug called ALXN2050 in 100 adults with kidney inflammation caused by lupus or IgA nephropathy. The goal was to see if it could reduce protein leaking into urine, a sign of kidney damage. The trial was stopped early, so results are limited, but researchers wer…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 11, 2026 12:11 UTC
-
Experimental drug targets protein leak in kidney patients
Disease control TerminatedThis study tested an experimental drug called OMS721 (narsoplimab) in 31 people with four different kidney diseases that cause protein in the urine. The main goal was to check safety and see if the drug could reduce protein leakage. The trial was stopped early, so results are lim…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 03, 2026 12:02 UTC